Cell MedX Corp (CMXC) reported a negative quarterly result for QQ2 2025, underscoring a precarious liquidity position despite ongoing device development. Net income stood at -$139,508 with an EPS of -$0.007, driven by operating expenses of $79,924 and a significant non-operating charge of -$139,508 (total other income/expenses net). The quarter shows no disclosed revenue, limiting visibility into top-line traction as management pursues commercialization of its eBalance Pro System and eBalance Home System. YoY comparisons indicate a material deterioration: net income is down 130.4% year-over-year and EPS down 600% over the same period. Management commentary (when available) would be critical to gauge path to profitability and capital strategy; however, the provided data does not include an earnings transcript to extract quotes or concrete forward-looking guidance.
On the balance sheet, CMXC exhibits extreme liquidity stress: cash and cash equivalents of $33,821 against total current liabilities of $665,274 and total liabilities of $1,021,051, resulting in an implausibly low current ratio of roughly 0.058. Negative stockholders’ equity (-$982,705) accompanies a debt load of $355,777, yielding a net debt position of approximately $321,956. Cash flow from operations was negative at -$16,519, further underscoring the need for external financing or a material reduction in burn. Given the absence of revenue data and the stark balance sheet, the near-term risk profile is dominated by liquidity and sustainability concerns rather than operating leverage.
In summary, the QQ2 2025 results portray a company at a crossroads: (1) potential upside from its diabetes/neuropathy device portfolio and remote/home-use systems, (2) but an immediate need to secure capital, reduce operating burn, and demonstrate revenue generation. The absence of earnings call transcripts in the provided data limits the ability to capture management’s qualitative outlook. Investors should closely monitor liquidity runway, any disclosed financing plans, milestones around product adoption, and potential partnerships that could unlock commercial value.